Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Zimmer Biomet Holdings / Equity Bottom-Up

<ul><li>Zimmer Biomet reported second quarter 2026 net sales of $2.177 billion, exceeding expectations with 4.8% reported growth and 4% organic growth on a constant currency basis.</li><li>U.S. sales rose 4.6%, led by a 5.9% increase in hips and growth in the S.E.T. segment (spine, extremities, trauma) of 3.4%.</li><li>Internationally, growth was more modest at 3.1%, with knee sales declining 1.5%, notably due to challenges in China and emerging markets.</li></ul>

Zimmer Biomet reported second quarter 2026 net sales of $2.177 billion, exceeding expectations with 4.8% reported growth and 4% organic growth on a constant currency basis.U.S. sales rose 4.6%, led by a 5.9% increase in hips and growth in the S.E.T. segment (spine, extremities, trauma) of 3.4%.Internationally, growth was more modest at 3.1%, with knee sales declining 1.5%, notably due to challenges in China and emerging markets.

Zimmer Biomet’s $2.177 Billion Quarter — Growth Improves As Margins Come Under Pressure!

Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

<ul>
  <li>Zimmer Biomet is a global leader in musculoskeletal healthcare, poised to benefit from demographic tailwinds such as an aging population and increasing rates of obesity and osteoarthritis.</li>
  <li>The company's strategic focus on innovation, particularly in robotic-assisted surgery with its ROSA platform, is a key growth driver, with technology sales showing robust expansion.</li>
  <li>While the company demonstrates strong operational execution and has raised forward guidance, it faces significant competition, pricing pressures from consolidated buyers, and a reliance on the successful adoption of new technologies.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  Zimmer Biomet is a global leader in musculoskeletal healthcare, poised to benefit from demographic tailwinds such as an aging population and increasing rates of obesity and osteoarthritis.
  The company's strategic focus on innovation, particularly in robotic-assisted surgery with its ROSA platform, is a key growth driver, with technology sales showing robust expansion.
  While the company demonstrates strong operational execution and has raised forward guidance, it faces significant competition, pricing pressures from consolidated buyers, and a reliance on the successful adoption of new technologies.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Zimmer Biomet Holdings (ZBH US) - Aug 2026

<ul><li>Zimmer Biomet began 2026 with solid operational execution, supported by improving product adoption trends, accelerating technology sales, disciplined margin management, and continued progress in its multiyear commercial transformation strategy.</li><li>Organic constant currency revenue grew 2.9%, landing at the upper end of the company’s annual growth guidance range, while adjusted earnings per share increased more than 15% year-over-year.</li><li>Revenue growth was supported by healthy reconstructive procedure demand, strong adoption of recently launched technologies, and robust momentum across robotics, data-driven surgical platforms, and specialized orthopedic products.</li></ul>

Zimmer Biomet began 2026 with solid operational execution, supported by improving product adoption trends, accelerating technology sales, disciplined margin management, and continued progress in its multiyear commercial transformation strategy.Organic constant currency revenue grew 2.9%, landing at the upper end of the company’s annual growth guidance range, while adjusted earnings per share increased more than 15% year-over-year.Revenue growth was supported by healthy reconstructive procedure demand, strong adoption of recently launched technologies, and robust momentum across robotics, data-driven surgical platforms, and specialized orthopedic products.

Zimmer Biomet: What Is Powering The Surge In Robotics, Navigation, And Connected Orthopedic Care?

<ul><li>Zimmer Biomet's latest earnings report underscores a complex landscape characterized by both opportunities and challenges.</li><li>The company's fourth-quarter 2025 performance was notable, marked by an organic constant currency sales growth of 5.4% and adjusted earnings per share of $2.42, reflecting a 4.8% year-over-year increase.</li><li>This performance was achieved despite confronting tariff headwinds, integration complexities from three acquisitions, and increased investments in their commercial organization.</li></ul>

Zimmer Biomet's latest earnings report underscores a complex landscape characterized by both opportunities and challenges.The company's fourth-quarter 2025 performance was notable, marked by an organic constant currency sales growth of 5.4% and adjusted earnings per share of $2.42, reflecting a 4.8% year-over-year increase.This performance was achieved despite confronting tariff headwinds, integration complexities from three acquisitions, and increased investments in their commercial organization.

Zimmer Biomet Is Going Global—Can Overseas Markets Reduce Its Reliance on the U.S.?

<ul><li>The third quarter of 2025 saw Zimmer Biomet deliver a mixed performance, demonstrating both strengths and areas of concern.</li><li>The company achieved a sales growth of 5% on an organic constant currency basis, highlighted by a significant improvement in its U.S. business, which increased by 5.6%.</li><li>Key product lines such as the Persona OsseoTi Cementless Total Knee and the Oxford Partial Cementless Knee showed strong adoption, contributing to an overarching success in the knee segment, which grew 5.3%.</li></ul>

The third quarter of 2025 saw Zimmer Biomet deliver a mixed performance, demonstrating both strengths and areas of concern.The company achieved a sales growth of 5% on an organic constant currency basis, highlighted by a significant improvement in its U.S. business, which increased by 5.6%.Key product lines such as the Persona OsseoTi Cementless Total Knee and the Oxford Partial Cementless Knee showed strong adoption, contributing to an overarching success in the knee segment, which grew 5.3%.

Zimmer Biomet: Can Its Surge in Knees and Hips Spark a Major Market Comeback?

United States

Zimmer Biomet Holdings, Inc. designs, develops, manufactures, and markets medical equipment. The Company offers orthopedic and dental reconstructive implants, spinal implants, trauma products, and related surgical products. Zimmer Biomet Holdings serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Zimmer Biomet Holdings (ZBH US)

Zimmer Biomet’s $2.177 Billion Quarter — Growth Improves As Margins Come Under Pressure!

Zimmer Biomet reported second quarter 2026 net sales of $2.177 billion, exceeding expectations with 4.8% reported growth and 4% organic growth on...

Baptista Research

Primer: Zimmer Biomet Holdings (ZBH US) - Aug 2026

Zimmer Biomet is a global leader in musculoskeletal healthcare, poised to benefit from demographic tailwinds such as an aging population and...

αSK Primers

Zimmer Biomet: What Is Powering The Surge In Robotics, Navigation, And Connected Orthopedic Care?

Zimmer Biomet began 2026 with solid operational execution, supported by improving product adoption trends, accelerating technology sales,...

Baptista Research

Zimmer Biomet Is Going Global—Can Overseas Markets Reduce Its Reliance on the U.S.?

Zimmer Biomet's latest earnings report underscores a complex landscape characterized by both opportunities and challenges. The company's...

Baptista Research

Zimmer Biomet: Can Its Surge in Knees and Hips Spark a Major Market Comeback?

The third quarter of 2025 saw Zimmer Biomet deliver a mixed performance, demonstrating both strengths and areas of concern. The company achieved a...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)